2026 Q3 - tulosraportti
UUTTA
6 päivää sitten
‧41 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 300 | ||
| 923 | ||
| 1 680 | ||
| 219 | ||
| 2 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenNot worth selling now at these levels. 🫣 I am down 85 %. 😅 I don't understand those who sell off in this situation. It's just not possible to get those amounts back on the little you get out. For that to happen, I need to place that money in a stock that will rise 600 %. 🤪 The only right thing for me is to ride along & hope that something good comes out of this.
·1 päivä sittenand the management with that old fool Martin is completely quiet and nothing about whether they themselves put skin in the game with larger amounts than the insignificant amount they started out announcing this is almost criminal with this dilution of us loyal old shareholders we have completely been fleeced holy crap how outrageous and petty criminal that is
1 päivä sittenNov 02, 2026 - Nov 04, 2026 Cancer R&D 2026, Houston Nov 04, 2026 - Nov 04, 2026 2026 BioStock Life Science Summit, Lund Nov 12, 2026 - Nov 12, 2026 Aktiespararna Digital Life Science night Nov 24, 2026 - Nov 24, 2026 Panel discussion at DNB Carnegie Nordic Healthcare Conference, Oslo
·1 päivä sitten · MuokattuTo get the desired amount in from the rights issue, the company needs to raise approx. 6.25 SEK in the issue per existing share. If we base it on the share price before the issue announcement of approx. 21 SEK, the share price should fall to approx. 13.75 SEK - but the drop should first occur on the day when the subscription rights were separated from the parent share. (approx. 21 kr + approx. 6.25 kr = approx. 27.50 kr in total for 2 shares after the issue or 13.75 SEK per share after the issue. This is the theoretical calculation. Redeye also arrives at a new target price of 24 SEK after having given the share a proper push downwards. Now the share price - thanks to the catastrophically dilettantish announcement - has already plummeted far below what a shareholder has to pay per old share, in order not to be diluted by the issue. This should not be able to happen when the company only needed to get approx. 1/3 of the share price home at the issue. But the management "managed" to smash the share so completely that an issue which could have been run sensibly has now derailed completely, and if the share price does not correct itself massively in the near future, things could unfortunately get even worse. If the share price does not correct itself, one cannot simply go out and demand 6.25 SEK for a new issue share, and then the issue will be distributed across more than one issue share per parent share E.g. split into subscription rights or units where you have to buy 10 shares at 62 øre instead, but the price is the same: cough up 6.25 SEK per current share if you do not want to be diluted. But surely a much more skewed number and distribution key between subscription rights and how many you need to have to buy a new share, so that few can figure it out. And surely at a lower price than the share price on the day of the price announcement, so one can claim that the shareholders get a new share with a 30% discount compared to the parent share. That is a pure smoke screen, as shown above. You still have to pay a total of 6.25 SEK per current share if you do not want to be diluted, regardless of how it is attempted to be veiled. The worst thing is that if one tries - and one most certainly does - to pretend a discount, the parent share just drops further by the corresponding 30% immediately after the announcement or at the latest after the completion of the issue or even further down, as is always seen in an issue that is carried out as hopelessly foolishly as this one. I hope that the parent share recovers during the coming month and gets above 6.25 SEK and well above 6.25 SEK, so the next disaster in the process is avoided. But unfortunately I cannot claim that I am optimistic right now. And if the parent share does not rise again, then there are no shareholders who will participate in the issue - and then the share goes to the underwriters at a spot price which - with the underwriting discount factored in - is even lower and which will presumably lead to a further push downwards on the share afterwards, as normally happens when the underwriters are not interested in being long-term shareholders. On the other hand: Was the share worth 21 SEK the other day, then nothing fundamental has happened yet that makes it not still worth the same. Or at least worth 13.75 SEK, if you - as the market always does currently with biotech issues - take your sorrows in advance and write down the share value already at the announcement of the issue and not first when the subscription rights actually detach from the share.
Yes I am mainly wondering if there is any company that has had the same journey where one can see how the share price developed and what decisions management made back then. Regarding the guarantors, I am really not worried about them, but I am mainly wondering which side it is that decided not to set a subscription price and if it could then be that the guarantors are a reason why it has been handled in this manner. Hard to say when one hasn't gotten any more info from the company than
·2 päivää sittenPrice target 83.7 🚀 🚀🚀 🚀🚀🚀🚀🚀🚀🚀 iActually it has dropped another 50% after the announcement, that's a bit wild..- ·2 päivää sittenOne could have had a 200% return if one bought in January 2024 and sold in September 2024...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 396 001 | 396 001 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 396 001 | 396 001 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
6 päivää sitten
‧41 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenNot worth selling now at these levels. 🫣 I am down 85 %. 😅 I don't understand those who sell off in this situation. It's just not possible to get those amounts back on the little you get out. For that to happen, I need to place that money in a stock that will rise 600 %. 🤪 The only right thing for me is to ride along & hope that something good comes out of this.
- ·1 päivä sittenand the management with that old fool Martin is completely quiet and nothing about whether they themselves put skin in the game with larger amounts than the insignificant amount they started out announcing this is almost criminal with this dilution of us loyal old shareholders we have completely been fleeced holy crap how outrageous and petty criminal that is1 päivä sittenNov 02, 2026 - Nov 04, 2026 Cancer R&D 2026, Houston Nov 04, 2026 - Nov 04, 2026 2026 BioStock Life Science Summit, Lund Nov 12, 2026 - Nov 12, 2026 Aktiespararna Digital Life Science night Nov 24, 2026 - Nov 24, 2026 Panel discussion at DNB Carnegie Nordic Healthcare Conference, Oslo
- ·1 päivä sitten · MuokattuTo get the desired amount in from the rights issue, the company needs to raise approx. 6.25 SEK in the issue per existing share. If we base it on the share price before the issue announcement of approx. 21 SEK, the share price should fall to approx. 13.75 SEK - but the drop should first occur on the day when the subscription rights were separated from the parent share. (approx. 21 kr + approx. 6.25 kr = approx. 27.50 kr in total for 2 shares after the issue or 13.75 SEK per share after the issue. This is the theoretical calculation. Redeye also arrives at a new target price of 24 SEK after having given the share a proper push downwards. Now the share price - thanks to the catastrophically dilettantish announcement - has already plummeted far below what a shareholder has to pay per old share, in order not to be diluted by the issue. This should not be able to happen when the company only needed to get approx. 1/3 of the share price home at the issue. But the management "managed" to smash the share so completely that an issue which could have been run sensibly has now derailed completely, and if the share price does not correct itself massively in the near future, things could unfortunately get even worse. If the share price does not correct itself, one cannot simply go out and demand 6.25 SEK for a new issue share, and then the issue will be distributed across more than one issue share per parent share E.g. split into subscription rights or units where you have to buy 10 shares at 62 øre instead, but the price is the same: cough up 6.25 SEK per current share if you do not want to be diluted. But surely a much more skewed number and distribution key between subscription rights and how many you need to have to buy a new share, so that few can figure it out. And surely at a lower price than the share price on the day of the price announcement, so one can claim that the shareholders get a new share with a 30% discount compared to the parent share. That is a pure smoke screen, as shown above. You still have to pay a total of 6.25 SEK per current share if you do not want to be diluted, regardless of how it is attempted to be veiled. The worst thing is that if one tries - and one most certainly does - to pretend a discount, the parent share just drops further by the corresponding 30% immediately after the announcement or at the latest after the completion of the issue or even further down, as is always seen in an issue that is carried out as hopelessly foolishly as this one. I hope that the parent share recovers during the coming month and gets above 6.25 SEK and well above 6.25 SEK, so the next disaster in the process is avoided. But unfortunately I cannot claim that I am optimistic right now. And if the parent share does not rise again, then there are no shareholders who will participate in the issue - and then the share goes to the underwriters at a spot price which - with the underwriting discount factored in - is even lower and which will presumably lead to a further push downwards on the share afterwards, as normally happens when the underwriters are not interested in being long-term shareholders. On the other hand: Was the share worth 21 SEK the other day, then nothing fundamental has happened yet that makes it not still worth the same. Or at least worth 13.75 SEK, if you - as the market always does currently with biotech issues - take your sorrows in advance and write down the share value already at the announcement of the issue and not first when the subscription rights actually detach from the share.Yes I am mainly wondering if there is any company that has had the same journey where one can see how the share price developed and what decisions management made back then. Regarding the guarantors, I am really not worried about them, but I am mainly wondering which side it is that decided not to set a subscription price and if it could then be that the guarantors are a reason why it has been handled in this manner. Hard to say when one hasn't gotten any more info from the company than
- ·2 päivää sittenPrice target 83.7 🚀 🚀🚀 🚀🚀🚀🚀🚀🚀🚀 iActually it has dropped another 50% after the announcement, that's a bit wild..
- ·2 päivää sittenOne could have had a 200% return if one bought in January 2024 and sold in September 2024...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 300 | ||
| 923 | ||
| 1 680 | ||
| 219 | ||
| 2 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 396 001 | 396 001 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 396 001 | 396 001 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
6 päivää sitten
‧41 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenNot worth selling now at these levels. 🫣 I am down 85 %. 😅 I don't understand those who sell off in this situation. It's just not possible to get those amounts back on the little you get out. For that to happen, I need to place that money in a stock that will rise 600 %. 🤪 The only right thing for me is to ride along & hope that something good comes out of this.
- ·1 päivä sittenand the management with that old fool Martin is completely quiet and nothing about whether they themselves put skin in the game with larger amounts than the insignificant amount they started out announcing this is almost criminal with this dilution of us loyal old shareholders we have completely been fleeced holy crap how outrageous and petty criminal that is1 päivä sittenNov 02, 2026 - Nov 04, 2026 Cancer R&D 2026, Houston Nov 04, 2026 - Nov 04, 2026 2026 BioStock Life Science Summit, Lund Nov 12, 2026 - Nov 12, 2026 Aktiespararna Digital Life Science night Nov 24, 2026 - Nov 24, 2026 Panel discussion at DNB Carnegie Nordic Healthcare Conference, Oslo
- ·1 päivä sitten · MuokattuTo get the desired amount in from the rights issue, the company needs to raise approx. 6.25 SEK in the issue per existing share. If we base it on the share price before the issue announcement of approx. 21 SEK, the share price should fall to approx. 13.75 SEK - but the drop should first occur on the day when the subscription rights were separated from the parent share. (approx. 21 kr + approx. 6.25 kr = approx. 27.50 kr in total for 2 shares after the issue or 13.75 SEK per share after the issue. This is the theoretical calculation. Redeye also arrives at a new target price of 24 SEK after having given the share a proper push downwards. Now the share price - thanks to the catastrophically dilettantish announcement - has already plummeted far below what a shareholder has to pay per old share, in order not to be diluted by the issue. This should not be able to happen when the company only needed to get approx. 1/3 of the share price home at the issue. But the management "managed" to smash the share so completely that an issue which could have been run sensibly has now derailed completely, and if the share price does not correct itself massively in the near future, things could unfortunately get even worse. If the share price does not correct itself, one cannot simply go out and demand 6.25 SEK for a new issue share, and then the issue will be distributed across more than one issue share per parent share E.g. split into subscription rights or units where you have to buy 10 shares at 62 øre instead, but the price is the same: cough up 6.25 SEK per current share if you do not want to be diluted. But surely a much more skewed number and distribution key between subscription rights and how many you need to have to buy a new share, so that few can figure it out. And surely at a lower price than the share price on the day of the price announcement, so one can claim that the shareholders get a new share with a 30% discount compared to the parent share. That is a pure smoke screen, as shown above. You still have to pay a total of 6.25 SEK per current share if you do not want to be diluted, regardless of how it is attempted to be veiled. The worst thing is that if one tries - and one most certainly does - to pretend a discount, the parent share just drops further by the corresponding 30% immediately after the announcement or at the latest after the completion of the issue or even further down, as is always seen in an issue that is carried out as hopelessly foolishly as this one. I hope that the parent share recovers during the coming month and gets above 6.25 SEK and well above 6.25 SEK, so the next disaster in the process is avoided. But unfortunately I cannot claim that I am optimistic right now. And if the parent share does not rise again, then there are no shareholders who will participate in the issue - and then the share goes to the underwriters at a spot price which - with the underwriting discount factored in - is even lower and which will presumably lead to a further push downwards on the share afterwards, as normally happens when the underwriters are not interested in being long-term shareholders. On the other hand: Was the share worth 21 SEK the other day, then nothing fundamental has happened yet that makes it not still worth the same. Or at least worth 13.75 SEK, if you - as the market always does currently with biotech issues - take your sorrows in advance and write down the share value already at the announcement of the issue and not first when the subscription rights actually detach from the share.Yes I am mainly wondering if there is any company that has had the same journey where one can see how the share price developed and what decisions management made back then. Regarding the guarantors, I am really not worried about them, but I am mainly wondering which side it is that decided not to set a subscription price and if it could then be that the guarantors are a reason why it has been handled in this manner. Hard to say when one hasn't gotten any more info from the company than
- ·2 päivää sittenPrice target 83.7 🚀 🚀🚀 🚀🚀🚀🚀🚀🚀🚀 iActually it has dropped another 50% after the announcement, that's a bit wild..
- ·2 päivää sittenOne could have had a 200% return if one bought in January 2024 and sold in September 2024...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 300 | ||
| 923 | ||
| 1 680 | ||
| 219 | ||
| 2 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 396 001 | 396 001 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 396 001 | 396 001 | 0 | 0 |